The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The Breakwater study hits on overall survival with "unprecedented" data.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The combined company's MALT1 inhibitor has started phase 1.
Crunch time approaches for UroGen.
